McMaster’s efforts to become an authoritative voice on optimal aging will be in the spotlight this week at two panel discussions featuring a roster of well-known speakers.
The public events are part of a larger initiative, Thinking Ahead: How We Can Better Support Optimal Aging in Canada Using the Best Available Research Evidence, which focuses on how we communicate with, engage and support Canada’s aging population. The initiative includes a two-day symposium for invited participants who are working directly in the field of aging.
Thinking Ahead has been organized by the McMaster Health Forum, and is funded by the Labarge Charitable Foundation in conjunction with University’s Labarge Optimal Aging Initiative.
Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder.
Researchers in the Farncombe Family Digestive Health Research Institute at McMaster University have discovered that a molecule, elafin, which is present in the intestine of healthy individuals, is significantly decreased in patients with celiac disease. The research was published in The American Journal of Gastroenterology.
"People who have to strictly avoid gluten for life often find this very difficult due to these hidden sources," said Elena Verdu, associate professor of medicine in the Michael G. DeGroote School of Medicine.